Goodwin Biotechnology, Inc., a biological contract development and manufacturing organization (CDMO) that specializes in bioprocess development and CGMP manufacturing of biopharmaceuticals utilizing mammalian cell culture expression systems and bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to develop a proof-of-concept conjugation of a fully-human monoclonal antibody to a radionuclide chelator to generate an antibody-chelator conjugate. The conjugate is subsequently labeled with indium-111 (111In) and other potential radioisotopes for in vivo diagnostic imaging and treatment of cancers. “Panacea has developed a…